Antineoplastics
1
Reactions 470 - 25 Sep 1993 ★ S Antineoplastics First report of tumour lysis syndrome in a patient with ovarian cancer: case report Tumour lysis syndrome (TLS) developed in a 47-year-old woman 4 days after she received carboplatin 400 mg/m 2 and cyclophosphamide 500 mg/m 2 for the treatment of advanced adenocarcinoma of the ovary. She had previously responded to 4 cycles of antineoplastic therapy with cyclophosphamide, carboplatin and doxorubicin after mastectomy for breast cancer. Ovarian cancer was first observed 2 months after the patient began tamoxifen therapy for a malignant pleural effusion. The patient’s levels of serum lactate dehydrogenase, uric acid, phosphate and creatinine increased, and serum calcium levels decreased. Treatment with a combination of IV fluids, parenteral bicarbonate, furosemide and allopurinol corrected most of these metabolic abnormalities within 48 hours. However, the woman died 3 weeks later because of rapid tumour growth. Author comment: ‘We report the first patient to develop TLS following combination chemotherapy for ovarian cancer. Patients at risk for developing TLS include those with a large tumor burden . . . These patients should be monitored for the development of metabolic abnormalities after therapy’. Bilgrami SFA, et al. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Medical and Pediatric Oncology 21: 521-524, No. 7, 1993 - USA 800221079 1 Reactions 25 Sep 1993 No. 470 0114-9954/10/0470-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 470 - 25 Sep 1993
★ SAntineoplastics
First report of tumour lysis syndrome in a patientwith ovarian cancer: case report
Tumour lysis syndrome (TLS) developed in a 47-year-oldwoman 4 days after she received carboplatin 400 mg/m2 andcyclophosphamide 500 mg/m2 for the treatment of advancedadenocarcinoma of the ovary. She had previously respondedto 4 cycles of antineoplastic therapy with cyclophosphamide,carboplatin and doxorubicin after mastectomy for breastcancer. Ovarian cancer was first observed 2 months after thepatient began tamoxifen therapy for a malignant pleuraleffusion.
The patient’s levels of serum lactate dehydrogenase, uricacid, phosphate and creatinine increased, and serum calciumlevels decreased. Treatment with a combination of IV fluids,parenteral bicarbonate, furosemide and allopurinol correctedmost of these metabolic abnormalities within 48 hours.However, the woman died 3 weeks later because of rapidtumour growth.
Author comment: ‘We report the first patient to develop TLSfollowing combination chemotherapy for ovarian cancer.Patients at risk for developing TLS include those with a largetumor burden . . . These patients should be monitored for thedevelopment of metabolic abnormalities after therapy’.Bilgrami SFA, et al. Tumor lysis syndrome after combination chemotherapy forovarian cancer. Medical and Pediatric Oncology 21: 521-524, No. 7, 1993 -USA 800221079
1
Reactions 25 Sep 1993 No. 4700114-9954/10/0470-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
